Novartis ESMO Event Presentation
Patients on Pluvicto demonstrated improved quality of life compared
to daily oral ARPI
FACT-P total score 1
HR: 0.59 (95% CI: 0.47, 0.72)
100
80
Event-free probability (%)
60
60
40
20
177 Lu-PSMA-617
ARPI change
BPI-SF pain intensity scale2
HR: 0.69 (95% CI: 0.56, 0.85)
100
80
Event-free probability (%)
60
60
60
420
20
177 Lu-PSMA-617
ARPI change
0
2
4
6
8
10 12 14
L6
T
T
16 18 20
0
2
4
6
8
10 12 14 16 18
20
Time from randomization (months)
Time from randomization (months)
Number of patients still at risk
43
96
234 199 160 130 101 38 12
234 174 115 64 39 20
7
8
32
95
27
1
0
234 190
138 108 88 39 12
2
0
234
159
105 61 42 24
82
1. FACT-P: Median time to worsening, months (95% CI): 7.5 (6.1, 8.5) vs. 4.3 (3.5, 4.5) 2. BPI: Median time to worsening, months (95% CI): 5.0 (4.4, 6.9) vs. 3.7 (3.1, 4.4)
20 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION
1
0
2
0
NOVARTIS | Reimagining MedicineView entire presentation